Bengaluru, July 2, 2019: Globally India is among the top three countries in terms of cancer incidences and mortality. India registers over 1,157,294 new cancer cases every year and 784,821 mortalities are attributed to this disease. And the cancer burden in the country has more than doubled in the past 26 years. Seeing the burgeoning scenario it is most important to bring in strategies to equip the healthcare sector to enable safe treatment now and in the years to come. Healthcare has volumes of data which can be evaluated to bring in outcome based treatment.
Oncology care has largely been driven by evidence based medicine and through the creation of protocols for treatment. Stanford University has already implemented outcome based treatment in the US. Healthcare Global Enterprises Limited (HCG) is associating with Dr. Jayanta Bhattacharya, M.D., Ph.D. Professor of Medicine at Stanford University on this tried and tested method. HCG is looking to leapfrog in the direction of precision medicine by making a calculated and organized start into evaluating Indian cancer care data collated over the years.
The wealth of data resting with HCG that includes predictive analysis, outcomes and even a patient’s response to a particular form of treatment would help to analyse and measure pointers that will offer the best course of treatment for a patient. By means of creating a scorecard for doctors & hospitals, patients will be able to review where HCG stands in comparison with global standards in treating a particular form of cancer, based on our own data and outcome measures.
Dr. B. S. Ajaikumar, Chairman & CEO, HealthCare Global Enterprises Limited said, “This is a very important and strategic association for us. It is now time for us to migrate from expensive treatments to a model where cost and outcomes are measured. When we put technology, advances in treatment and talent together, we can achieve global standards of outcome, which defines quality of care. I am sure that with time and enough research on this, we would be the forerunners in India providing cost-effective and outcome-based treatments.”
Speaking on the collaboration with HCG, Dr. Jayanta Bhattacharya M.D., Ph.D., Professor of Medicine, Stanford University said, “India and the US have similar issues in healthcare and it is all about providing treatment that has monetary value to the patient. Enforcing a link between cost and outcome is very important in a low resource environment like India. Data is the right way to go and when analyzed correctly, this data would help us reach the desired outcomes. My goal, along with HCG’s goal is to improve healthcare step by step and I am confident that using lessons learned in the American context and applying it to the Indian scenario, we would be able to positively change the way forward.”
HCG aims to make each of its units into Centres of Excellence by offering the right treatment at the right time, thereby reducing recurrences and improving outcomes.
Corporate Comm India(CCI NewsWire)
